Introduction
============

Cervical cancer is the fourth most frequent cancer in women worldwide(Bruni et al., 2017) which remains a leading cause of cancer-related death for women in developing countries. As known, it is a well-controlled disease in industrialized countries because of Papanicolaou (PAP) test and effective screening program implementation. (Sherris et al., 2001; Catarino et al., 2015; Torre et al., 2017) Disease prevalence is decreasing in those population. Further attention should be paid in specific screening algorithm to enhance the efficacy of screening protocols. It is well known that cervical cancer is preceded by high grade intraepithelial lesion (HSIL) which follows persistent human papillomavirus (HPV) infection.

In fact, active transcription of HPV oncogene can be directly detected by E6/E7 viral mRNA transcripts and indirectly detected by accumulation of the host protein p16 in the cell. It has been widely reported that p16 expression is affected by the high risk HPV E7 protein and its up-regulation increasing severity of cervical lesions. (Giarrè et al., 2001; Li et al., 2011) Protein p16, a tumor suppressor from the Ink4 family, encoded by CDKN2A gene (9p21.3) prevents progression into S phase of cell cycle by inhibits cyclin D dependent protein kinases (CDK4 and CDK6) therefore maintaining retinoblastoma protein (pRb) in its hypophosphorylated state which prevents its dissociation from E2F transcription factor. Integration of viral E7 oncoprotein integrate into host genome leads to inactivation of pRb and overexpression of p16, therefore p16 protein immunohistochemistry (p16 IHC) is surrogate marker of high risk HPV infection. (Sano et al., 1998; Klaes et al., 2001; Negri et al., 2004; Queriroz et al., 2006; Iaconis et al., 2007)

The main objective of the present study was to assess the association of the overexpression of p16 IHC and progression of cervical intraepithelial neoplasia (CIN) 1 to CIN2 or worse (CIN2+) or recurrence of CIN2+ after treatment during follow up in women who had a colposcopy-directed biopsy (CDB).

Materials and Methods
=====================

A retrospective cohort study, the women who newly diagnosed SIL from CDB at the Department of Obstetrics and Gynecology of Rajavithi Hospital, Bangkok from January 2013 to June 2017, all the patients showing histologically confirmed precancerous cervical lesion at an initial evaluation and followed up at least 1 year from the date of histologic diagnosis by CBD to the last visit were included in this study.

*Study design and Population*

Patients whom diagnosed precancerous cervical lesion from CBD including HPV CIN1 CIN2 CIN3 were recruited, H and E slide were recut and reviewed with blinding previous diagnosis. Then p16 IHC were stained and interpreted by same pathologist in different time. Positive staining was defined as "block" staining: strong abnormal nuclear and cytoplasmic expression in a continuous segment of cells (at least 10 - 20 cells); in squamous epithelium, block positivity needs to involve basal and parabasal layers. Cytoplasmic only staining, diffuse blush / weak intensity staining / other focal / patchy patterns should be considered negative as. (Darragh et al., 2012; Kurman et al., 2014) The exclusion criteria were previous history of SIL, cervical cancer and absent paraffin block. Patients who underwent see & treat strategy were not analyzed.

*Follow-up and Outcome*

All patients underwent standard treatment during followed up, when abnormal cytology screening (ASCUS or worse) was presented, cervical tissue was confirmed by CDB. After diagnosis of precancerous cervical lesion, patients with low-grade lesions (HPV or CIN1) were observed every 6 months by conventional pap test or Liquid-based cytology at each follow-up while patients with high-grade lesion had intervention as standard protocol either Loop Electrosurgical Excision Procedure (LEEP) or local ablation then patients were followed up with cytology every 6 months. If there was any abnormality, CDB was done to confirm histologic diagnosis but in case of normal colposcopy, CBD was not performed. The outcome was measured by disease free interval(DFI) which was the time from diagnosis to progression to CIN2+ in case HPV/CIN1 or the time from diagnosis to recurrence to CIN2+ in case CIN2-3 after treatment (Health, 2014).

*Statistical Analysis*

The study sample size was estimated based on the formula for two independent proportion formula of **Bernard (2000)???** with 1:1 ratio, a proportion in group 1 of 0.250 and group 2 of 0.029 from study of Razmpoosh et al., (2014) were incorporated into the calculation. All data was analyzed using STATA program fifteenth version, the descriptive analysis were described by mean, SD, median, range for numerical data and using proportion, percentage for categorical data. The inferential analysis was compared by Student t-test, Chi-square test, Fisher exact test. The 95% confidence intervals (CI) were carried out using the Cox proportional hazard regression model. A value of p \< 0.05 was considered statistically significant.

Results
=======

The 263 women who newly diagnosed SIL were recruited, then 76 women who absented paraffin block were excluded. Finally, 187 women were analyzed by p16 IHC staining. Ninety-one women were positive for p16 IHC staining and 96 women were negative for p16 IHC staining.

The baseline characteristics including age parity smoking and immunocompromised status were balance but initial histology and treatment were statistically significant difference as summarized in [table1](#T1){ref-type="table"}. The mean age of participants was 40.82 and 42.31 years in positive p16 and negative p16 staining respectively, most of them were multi-parity no smoking and no underlying immunocompromised status. Mostly, LSIL were negative p16 about 77.7% and progressed to CIN2+ only 3.6% while the progression of positive p16 LSIL was 16.7% In contrast, HSIL found 84.8% of HSIL had positive p16 and recurrence were 17.9% as shown in [Table 2](#T2){ref-type="table"}.

The Kaplan Meier curve for 1-year DFI showed that women who had positive p16 had significantly lower than negative p16 (86.8% vs. 96.6%; p = 0.003) with the median follow up time of 22 months as [Figure 1](#F1){ref-type="fig"}. The univariate analysis of variable associated progression or recurrence to CIN2+ revealed that prognostic factors were age, initial histology, and p16 staining. After performing the multivariate analysis, it showed the p16 IHC and age \> 35 years were significant prognostic factors for poor outcomes after adjust other factors ([Table 3](#T3){ref-type="table"}).

The Subgroup analysis of Prognostic Factors Related to Progressive CIN2+, positive p16 was important prognostic factor with significant difference in women diagnosed with low-grade lesion ([Table 4](#T4){ref-type="table"}). 1-year DFI in those with positive p16 IHC (91.7%) was lower than those with negtive p16 (98.8%) with significant difference, which was confirmed by the Kaplan Meier curve for 1-year DFI of p16 IHC and progressive CIN2+ in [Figure 2a](#F2){ref-type="fig"}. However, in women diagnosed with high-grade lesion, positive p16 was not significantly associated recurrence to CIN2+ after treatment ([Table 5](#T5){ref-type="table"}) which shown in the Kaplan Meier curve of DFI in [Figure 2b.](#F2){ref-type="fig"}

![The Kaplan Meier Curve for 1 Year DFI of p16 IHC and Progressive/recurrent CIN2+](APJCP-20-1809-g001){#F1}

![The Kaplan Meier Curve for 1 Year DFI of p16 IHC and Progressive CIN2+ in LSIL (a) and HSIL (b)](APJCP-20-1809-g002){#F2}

###### 

The Baseline Characteristics

  Characteristics              Positive p16   Negative p16   p-value            
  ---------------------------- -------------- -------------- --------- -------- ------------
  Age (yrs.), mean (SD)†       40.82          (12.5)         42.31     (11.1)   0.39
  Parity ‡                                                                      
  Nulliparity                  17             (19.5)         15        \(16\)   0.563
  Multiparity                  74             (80.5)         79        \(84\)   
  Immunocompromised status ‡   7              (7.7)          10        (10.4)   0.517
  Smoking §                    1              (1.1)          2         (2.1)    0.999
  Histology ‡                                                                   
  LSIL                         24             (22.6)         84        (77.4)   \< 0.001\*
  HSIL                         67             (86.7)         12        (13.3)   
  Treatment ‡                                                                   
  None                         33             (36.3)         72        \(75\)   \< 0.001\*
  LEEP                         55             (60.4)         24        \(25\)   
  Hysterectomy                 3              (3.3)          0         0        

HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous intraepithelial lesion; p16, p16 protein-immunohistochemistry; SD, standard deviation; \*, Significance at p-value less than 0.05; †Student t-test, ‡, Chi-square test; §, Fisher-exact test.

###### 

Progression of Precancerous Cervical Lesion Associated with p16 IHC Staining

                                 Total (%)   Progressive/recurrent CIN2+ (%)
  ----------- ------------------ ----------- ---------------------------------
  LSIL        Negative p16 IHC   84 (77.7)   3 (3.6)
  (N = 108)   Positive p16 IHC   24 (22.2)   4 (16.7)
  HSIL        Negative p16 IHC   12 (15.2)   1 (8.3)
  (N = 79)    Positive p16 IHC   67 (84.8)   12 (17.9)

CIN2+, cervical intraepithelial neoplasia 2 or worse; p16 IHC, p16 protein-immunohistochemistry staining

![Benchmark of Cumulative Risk of CIN2+ Following CIN1/Negative Colposcopy Given Antecedent HSIL+, ASC-H, AGC, and LSIL/HPV+/ASC-US, among Women Aged 25 and Older (Katki et al, 2013). The progressive risk of LSIL with p16 staining positive (cross) and negative (dot) from this study](APJCP-20-1809-g003){#F3}

###### 

Factor Associated with Progressive or Recurrent to CIN2 or Worse

  --------------------------------------------------------------------------------------------------------------------------------------
  Variables           N     Progressive/ recurrent\   Crude HR   95% CI   P-value        Adjusted HR   95% CI   P-value        
                            CIN2+ (%)                                                                                          
  ------------------- ----- ------------------------- ---------- -------- -------------- ------------- -------- -------------- ---------
  Age                                                                                                                          

  \< 35 yrs.          62    2                         (3.2)                                                                    

  \> 35 yrs.          125   18                        (14.4)     4.86     (1.13-20.97)   0.034\*       5.8      (1.34-25.08)   0.019\*

  Parity                                                                                                                       

  Nulliparity         33    3                         (9.1)                                                                    

  Multiparity         154   17                        \(11\)     1.41     (0.41-4.84)    0.588                                 

  HIV infection                                                                                                                

  No                  170   20                        (11.8)                                                                   

  Yes                 17    0                         0                                                                        

  Smoking                                                                                                                      

  No                  184   20                        (10.9)                                                                   

  Yes                 3     0                         0                                                                        

  Initial histology                                                                                                            

  LSIL                108   7                         (6.5)                                                                    

  HSIL                79    13                        (16.5)     2.8      (1.12-7.03)    0.028\*                               

  p16 IHC staining                                                                                                             

  Negative            96    4                         (4.2)                                                                    

  Positive            91    16                        (17.6)     4.65     (1.55-13.93)   0.006\*       5.33     (1.77-16.01)   0.003\*

  Treatment                                                                                                                    

  Observation         105   10                        (9.5)                                                                    

  LEEP                79    9                         (11.4)     1.27     (0.52-3.13)    0.6                                   

  Hysterectomy        3     1                         (33.3)     4.42     (0.56-34.73)   0.158                                 
  --------------------------------------------------------------------------------------------------------------------------------------

CIN2+, cervical intraepithelial neoplasia 2 or worse; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous intraepithelial lesion; p16 IHC, p16 protein-immunohistochemistry; \* Significance at p-value less than 0.05; †, Student t-test; ‡, Chi-square test, §Fisher-exact test

###### 

Factor Associated with Progressive to CIN2 or Worse in LSIL

  Variables          N     Progressive CIN2+ (%)   Crude HR   95% CI   P-value        
  ------------------ ----- ----------------------- ---------- -------- -------------- ---------
  Age                                                                                 
  \< 35 yrs.         32    2                       (6.25)                             
  \> 35 yrs.         72    5                       (6.94)     1.4      (0.27-7.26)    0.684
  Parity                                                                              
  Nulliparity        21    1                       (4.76)                             
  Multiparity        87    6                       (6.9)      1.54     (0.18-12.80)   0.691
  HIV infection                                                                       
  No                 97    7                       (7.22)                             
  Yes                11    0                                                          
  Smoking                                                                             
  No                 107   7                       (6.54)                             
  Yes                1     0                                                          
  p16 IHC staining                                                                    
  Negative           84    3                       (3.57)                             
  Positive           24    4                       (16.67)    5.29     (1.18-23.76)   0.030\*
  Treatment                                                                           
  Observation        93    7                       (7.53)                             
  LEEP               15    0                                                          

CIN2+, cervical intraepithelial neoplasia 2 or worse; LEEP, loop electrosurgical excision procedure; p16 IHC, p16 protein-immunohistochemistry

\*Significance at p-value less than 0.05

###### 

Factor Associated with Recurrent to CIN2 or Worse in HSIL

  Variables          N    Recurrent CIN2+ (%)   Crude HR   95% CI   P-value        
  ------------------ ---- --------------------- ---------- -------- -------------- -------
  Age                                                                              
  \< 50 yrs.         58   9                     (15.51)                            
  \> 50 yrs.         21   4                     (19.05)    1.32     (0.41-4.29)    0.644
  Parity                                                                           
  Nulliparity        12   2                     (16.67)                            
  Multiparity        67   11                    (16.42)    1.29     (0.27-6.09)    0.743
  HIV infection                                                                    
  No                 73   13                    (17.81)                            
  Yes                6    0                                                        
  Smoking                                                                          
  No                 77   13                    (16.88)                            
  Yes                2    0                                                        
  p16 IHC staining                                                                 
  Negative           12   1                     (8.33)                             
  Positive           67   12                    (17.91)    2.13     (0.28-16.38)   0.468
  Treatment                                                                        
  Observation        12   3                     \(25\)                             
  LEEP               64   9                     (14.06)    0.64     (0.17-2.41)    0.511
  Hysterectomy       3    1                     (33.33)    1.84     (0.19-18.20)   0.601

CIN2+, cervical intraepithelial neoplasia 2 or worse; LEEP, loop electrosurgical excision procedure; p16 IHC, p16 protein-immunohistochemistry

\*Significance at p-value less than 0.05

###### 

Comparation of Previous Studies

  Author (yr)               N     Baseline   p16 IHC (%)   F/U time (mo.)   Progress CIN2+   Results
  ------------------------- ----- ---------- ------------- ---------------- ---------------- ----------------------
  Razmpoosh (2014)(15)      64    CIN1       27.4          \> 6             25.00%           p = 0.002
  Liao (2014)(16)           171   Normal     42.7          24               10.70%           RR 8.25 (1.02-66.62)
                                  CIN1                                                       
  Pacchiarotti (2014)(17)   124   Normal     50.8          24               10.30%           RR 5.20 (0.60-47.50)
                                  CIN1                                                       
  Sagasta (2016)(18)        416   HPV        11.3          28               22.40%           HR 1.6 (0.9--2.6)
                                  CIN1                                                       
  This study                108   HPV        22.2          22               16.70%           HR 5.29 (1.18-23.76)
                                  CIN1                                                       

Discussion
==========

In the present study, SIL with positive p16 staining was likely progressed or recurred to CIN2+ with significant difference. Therefore, it is possible that p16 overexpression might be used as a predictor among the patients who diagnosed with SIL. Low-grade lesion with positive p16 staining was likely to progressed about 5.29 times compared to those with negative p16 staining. From previous studies, approximately 10-25% of CIN1 with positive p16 staining progressed to CIN2+ ([Table 6](#T6){ref-type="table"}) which were similar to our study. However, the results from those studies were inconclusive. The statistical difference was obvious in 2 studies (Liao et al., 2014; Razmpoosh et al., 2014) whereas not statistically different in another 2 studies (Pacchiarotti et al., 2014; Sagasta et al., 2016). In the present study, high-grade lesion with positive p16 staining had recurrence to CIN2+ about 2.13 times than those with negative p16 staining but it was not significantly different. It is well known that status of LEEP's margin predicts the outcome of treatment, women who have positive excisional margin trend to recur more than those who have negative margin. In the present study, the proportion of women who have positive margin was not identified therefore we do not know exactly how many patients at risk for recurrence in our population. If p16 test is performed in particular group such as women with positive margin, it may be useful and further study in this area is needed.

Base on the concept of equal management of equal risk theory (Katki et al., 2013) in Figure 5, progressive risk of LSIL with negative p16 staining (dot) from the present study is lower than benchmark of Cumulative risk of CIN2+ at 1 year after CIN1/ negative colposcopy by antecedent LSIL / positive HPV DNA ASCUS. These patient might be reassured for follow up without treatment by cotesting at 1 year later followed by ASCCP guideline (Massad et al., 2013). While the progressive risk of LSIL with positive p16 staining (cross) is higher than benchmark (Katki et al., 2013) therefore these patient may benefit more from excision procedure but further studies in larger population is required to confirm these findings.

The important strength of the present study is all slides were histologically reviewed for decrease selective bias and the p16 IHC staining and H and E slides were interpreted by the same pathologist in different time and blinding of result. The present study has some limitation. First, the retrospective study leads to incomplete data collected and information bias. Second, a significant loss of paraffin blocks might render the data not representing the actual population.

In conclusion, the overexpression of p16 protein was the significant prognostic factor of SIL. By using the p16 IHC may help stratify patients as low-risk and high-risk groups to predict progression or recurrence CIN2+.
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